Vaccinex Inc Stock Price, News & Analysis

Vaccinex has partnered with two undisclosed pharmaceutical companies to leverage its ActivMAb® platform for antibody discovery, focusing on complex antigens like GPCRs and ion channels. These collaborations aim to enhance vaccine development and therapeutic solutions. The terms of these agreements remain undisclosed. The ActivMAb technology is known for its ability to identify unique antibodies against challenging targets, which could lead to advancements in treatment options for various diseases. Vaccinex's lead candidate, pepinemab, is also highlighted for its potential in treating neurodegenerative diseases.

Vaccinex (Nasdaq: VCNX) announced its participation in the 10th Annual LifeSci Partners Corporate Access Event from January 6-8 and 11-14, 2021. Maurice Zauderer, Ph.D., will present a corporate update and host 1x1 meetings on January 6th at 11 am EST. The company is focused on treating neurodegenerative diseases with its lead candidate, pepinemab, which inhibits SEMA4D. Pepinemab shows promise for conditions like Huntington’s and Alzheimer’s and is in trials with checkpoint inhibitors for oncology applications.

Vaccinex, Inc. (Nasdaq: VCNX) announced its financial results for Q3 2020, ending with cash and cash equivalents of $17.1 million. While the SIGNAL phase 2 trial for Pepinemab in Huntington's disease did not meet co-primary endpoints, encouraging metrics suggest further development is warranted. The company plans to initiate a Phase 1b/2 trial of Pepinemab with KEYTRUDA for head and neck cancer in H1 2021 and a Phase 1/2 study for Alzheimer's disease in 2021, with partial funding from prominent associations.

Vaccinex, Inc. (Nasdaq: VCNX) announced positive findings from its Phase 2 SIGNAL study of pepinemab in treating Huntington's disease (HD). The data suggests cognitive benefits and reduced brain atrophy in HD patients. CEO Dr. Maurice Zauderer will present the findings at the Huntington Study Group conference from October 29-31, 2020. Key analyses show significant treatment benefits and well-tolerated safety profiles, supporting further development of pepinemab for HD and other neurodegenerative diseases like Alzheimer's.

Vaccinex, Inc. (Nasdaq: VCNX) announced promising results from its Phase 2 SIGNAL trial of pepinemab for Huntington's disease (HD), presented during the Huntington Study Group conference. The data indicate significant cognitive benefits and reduced brain atrophy in HD patients treated with pepinemab. Key findings include strong improvements in the HD-Cognitive Assessment Battery and clinical assessments. The company aims to further develop pepinemab for HD and other neurodegenerative diseases. Safety data show good tolerability and low dropout rates, supporting its potential for combination therapies.

Vaccinex, Inc. (Nasdaq: VCNX) has announced a live moderated video webcast featuring management and KOL Eric Siemers, MD on October 27, 2020, at 10:00 AM EDT. The discussion will cover insights from the SIGNAL phase 2 study in Huntington’s disease, its implications for Alzheimer’s disease, and a review of the combination treatment of pepinemab with Keytruda^® for Head & Neck Cancer. The event will be accessible via the Investors section of Vaccinex’s website, with a replay available two hours after the live session.

Vaccinex, Inc. (Nasdaq: VCNX) announced topline results from its Phase 2 SIGNAL trial of pepinemab in Huntington's disease patients. Although the study did not meet its co-primary endpoints, cognitive assessments showed a trend towards improvement. Pepinemab was well-tolerated, with low discontinuation rates. The company plans to initiate a new study for Alzheimer's disease and expects to balance its budget to support ongoing research. The results indicate that patients with greater cognitive deficits may benefit more from pepinemab treatment.

Vaccinex (Nasdaq: VCNX) announced a clinical collaboration with Merck to assess the combination of its SEMA4D inhibitor, pepinemab, and Merck's KEYTRUDA^® for treating advanced head and neck squamous cell carcinoma (HNSCC). The study will include a dose escalation phase and an expansion phase with up to 65 patients, focusing on enhancing immunotherapy efficacy. Key endpoints will encompass objective response, progression-free survival, and overall survival. Pepinemab has shown promise in preclinical studies for enhancing immune responses in tumors.

Vaccinex, Inc. (Nasdaq: VCNX) announced the appointment of Robert Scala as Chief Commercial Officer, effective immediately. Scala will oversee all commercial functions and strategic operations for the company, starting with pepinemab, a potential treatment for Huntington’s disease. With over 30 years of experience in neurology, oncology, and immunology, Scala previously held leadership roles at biotechnology firms and major pharmaceutical companies. This appointment signifies a pivotal growth phase for Vaccinex, enhancing its commercial capabilities in addressing the unmet needs in Huntington’s disease.